Company Filing History:
Years Active: 2021-2022
Title: Jack Chang Hung Lee: Innovator in Pharmaceutical Research
Introduction
Jack Chang Hung Lee is a notable inventor based in Mystic, CT (US). He has made significant contributions to the field of pharmaceutical research, particularly in the development of inhibitors for diacylglycerol acyltransferase 2 (DGAT2). With a total of 2 patents, his work is paving the way for advancements in treating conditions such as non-alcoholic steatohepatitis (NASH).
Latest Patents
Jack's latest patents focus on compounds that serve as DGAT2 inhibitors. These compounds are described in detail as Formula (I), where various R groups are defined. The pharmaceutical compositions containing these inhibitors are intended for use in treating NASH, showcasing the potential impact of his research on public health.
Career Highlights
Jack is currently employed at Pfizer Corporation, a leading global pharmaceutical company. His role involves extensive research and development, contributing to innovative solutions in the healthcare sector. His expertise in the field has positioned him as a valuable asset to his team and the company.
Collaborations
Jack has collaborated with notable colleagues, including David James Edmonds and Kevin James Filipski. These partnerships enhance the collaborative spirit of innovation within the pharmaceutical industry.
Conclusion
Jack Chang Hung Lee's contributions to pharmaceutical research, particularly in the area of DGAT2 inhibitors, highlight his role as an influential inventor. His work not only advances scientific knowledge but also holds promise for improving patient outcomes in the treatment of NASH.